Department / Division:
Medicine / Cardiology

Address:
2400 Pratt Street, Room 0311 Terrace Level
Durham, NC 27750

DUMC Box 3850
Durham, NC 27710

Appointment Telephone:
919-681-5816

Office Telephone:
919-668-8845

Fax Telephone:
919-668-7059

• MD, University of Washington School of Medicine, 1989

• Internal Medicine, University of Arizona Health Sciences Center, Tucson VA Medical Center, 1989-1993
• Cardiology, Duke University Medical Center, 1993-1996

Clinical Interests:
Acute coronary care, acute myocardial infarction, unstable angina, congestive heart failure

Research Interests:
My primary research focus is the design and conduct of randomized clinical trials and analyses of important clinical cardiac issues using large patient databases.  Clinical research interests include the evaluation of glycoprotein IIb/IIIa receptor antagonists in the acute coronary syndrome, the study of agents to prevent reperfusion injury in acute myocardial infarction, the analysis of cardiac enzyme elevations in patients with acute coronary syndromes, the identification of risk factors for stroke in patients with acute coronary syndromes, and the study of thrombolysis-related intracranial hemorrhage.

I am also interested in the methodology of clinical trials.  My current interests include standardization of the definition of myocardial infarction used in clinical trials and the adjudication of suspected clinical endpoint events in large multicenter studies.  I have helped develop efficient strategies to classify clinical endpoints and supervise the event review effort in trials coordinated at the Duke Clinical research Institute.

Representative Publications:
Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, Eisenberg PR, Bolli R, Casa AC, Molina-Viamonte V, Orlandi C, Blevins R, Gibbons RJ, Califf RM, Granger CB for the AMISTAD Investiators. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: Results of a multicenter, randomized, placebo controlled trial. The Acute Myocardial Infarction STudy of ADenosine (AMISTAD) Trial. J Am Col Cardiol 1999;34:1711-1720. (1999)

4. Mahaffey KW, Harrington RA, Simoons ML, Granger CB, Graffagnino C, Alberts MJ, Laskowitz DT, Miller JM, Sloan MA, Berdan LG, MacAulay6 CM, Lincoff AM, Deckers, J, Topol EJ, Califf RM for the PURSUIT Investigators. Stroke in patients with acute coronary syndromes: Incidence and outcomes in the PURSUIT trial. Circulation 1999;99:2371-2377. (1999)

3. Mahaffey KW, Granger CB, Sloan MA, Thompson T, Gore JM, Weaver WD, White HD, Simoons ML, Barbash GI, Topol EJ, Califf RM for the GUSTO-I Investigators. Risk factors for in-hospital non-hemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: Results from GUSTO-I. Circulation 1998/97:757-764. (1998)

2. Mahaffey KW, granger CB, Toth CA, White HD, Stebbins AL, Barbash GI, Vahanian A, Topol EJ, Califf RM for the GUSTO-I Investigators. Diabetic retinopathy should not be a contraindication for thrombolytic therapy for acute myocardial infarction: Review of ocular hemorrhage incidence and location in the GUSTO-I trial. J AM Coll Cardiol 1997;30:1606-1610. (1997)

1. Mahaffey KW, Granger CB, Collins R, O'Connor CM, Ohman EM, Bleich SD, Col JJ, Califf RM. Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol 1995;77:551-556. (1995)